Impact of treatment interruption on the efficacy and safety of vunakizumab in patients with moderate-to-severe plaque psoriasis: a post-hoc analysis of a phase 3 trial
ObjectiveVunakizumab, a novel IL-17A inhibitor, has demonstrated satisfactory efficacy and safety for the treatment of moderate-to-severe plaque psoriasis. This analysis aimed to assess the impact of treatment interruption on the efficacy and safety of…